key: cord-0884198-eoq73jk6 authors: Jeelan Basha, N.; Basavarajaiah, S. M.; Shyamsunder, K. title: Therapeutic potential of pyrrole and pyrrolidine analogs: an update date: 2022-01-25 journal: Mol Divers DOI: 10.1007/s11030-022-10387-8 sha: af9f098b889947c0548ef9a1db6010c98c498579 doc_id: 884198 cord_uid: eoq73jk6 The chemistry of nitrogen-containing heterocyclic compound pyrrole and pyrrolidine has been a versatile field of study for a long time for its diverse biological and medicinal importance. Biomolecules such as chlorophyll, hemoglobin, myoglobin, and cytochrome are naturally occurring metal complexes of pyrrole. These metal complexes play a vital role in a living system like photosynthesis, oxygen carrier, as well storage, and redox cycling reactions. Apart from this, many medicinal drugs are derived from either pyrrole, pyrrolidine, or by its fused analogs. This review mainly focuses on the therapeutic potential of pyrrole, pyrrolidine, and its fused analogs, more specifically anticancer, anti-inflammatory, antiviral, and antituberculosis. Further, this review summarizes more recent reports on the pyrrole, pyrrolidine analogs, and their biological potential. GRAPHICAL ABSTRACT: [Image: see text] Heterocycles are cyclic compounds that have at least one different element than carbon, such as sulfur, oxygen, nitrogen [1] . These heterocycles have received considerable attention because of their biological and pharmacological significance [2] [3] [4] [5] . One of the heterocycles, pyrrole, is not naturally derived, but its analogs present in co-factors and natural products such as vitamin B12, bile pigments: bilirubin and biliverdin [6, 7] , and the porphyrins of heme, chlorophyll, chlorins, bacteriochlorins, and porphyrinogens [8] [9] [10] [11] . Pyrrole-containing secondary metabolites such as makaluvamine M, ryanodine, rhazinilam, lamellarin, prodigiosin, myrmicarin, and sceptrinare also exhibit potential biological activity [12] [13] [14] [15] [16] [17] [18] [19] . Apart from this, pyrrole and pyrrolidine analogs have diverse therapeutic applications like fungicides, antibiotics, anti-inflammatory drugs, cholesterol-reducing drugs, anti-tubercular, and antitumor agents [20] [21] [22] [23] [24] [25] . These are also known to inhibit reverse transcriptase in case of human immune deficiency virus type 1 (HIV-1) and cellular DNA polymerases protein kinases [26, 27] . The combination of different pharmacophore in a pyrrole and pyrrolidine ring system has led to more active compounds [28] [29] [30] [31] [32] . In naturally occurring metal complexes heme (1) and chlorophyll (2) , four pyrrole rings are linked together to form porphyrin and then coordinate with iron and magnesium to form respective metal complexes ( Fig. 1 ) [33] . These heme groups, surrounding a globin group, produce a tetrahedral structure known as hemoglobin, an oxygen carrier in animals [34] . Unlike hemoglobin, biomolecule myoglobin traps oxygen within muscle cells for energy production required for muscles to contract [35] . An essential biomolecule, vitamin B12, porphyrin, and cobalt metal complex, forms through the stable metal-carbon bond and plays a vital for proper growth (3 a-d) [36] . Further, the bile pigments (4) are obtained by the decomposition of the porphyrins ring. Formation of this yellowish pigment takes place in spleen, reticulo endothelial cells of the liver, and bone marrow [37] . Another pyrrole analog is ageliferin (5a), produced by sponges. First isolated from the caribbean and then okinawan marine sponges have potential antibacterial properties [38] . Similarly, nargenicin (5b) is isolated from Nocardia argeninensis found to be more effective against gram-positive bacteria [39] (Fig. 2) . Similarly, pyrrolidine analogs including nicotine (6a), scalusamide (6b), bgugaine (6c), D-ribitol (6d), and aegyleptolidine (6e) showing diverse biological activities have been derived from natural sources and microorganisms [40, 41] (Fig. 3 ). Nitrogen-containing heterocycles have been known for their therapeutic potential. Among medicinal drugs, many are containing pyrrole and pyrrolidine moiety [42, 43] . Some of the drugs have pyrrole, pyrrolidine moieties are already available in market, and some are under clinical trials. The following are the pyrrole, pyrrolidine (saturated pyrrole) drug candidates. Pyrrolidine (saturated pyrrole) analog; telaprevir is an antiviral drug, peptidomimetic used in combination therapy to treat chronic Hepatitis C Virus (HCV) infection. This drug inhibits NS3/4A, a serine protease encoded by HCV genotype 1 and SARS-CoV-2 3CL proteases. Also, this drug is used with pegylated interferon and ribavirin for clinical trials [44] [45] [46] (Fig. 4 ). Ramipril is a competitive inhibitor of ACE, angiotensinconverting enzyme (ACE), responsible for the conversion of angiotensin I (ATI) to angiotensin II (ATII) and regulates blood pressure. Ramipril is used to treat hypertension, congestive heart failure, and to control the death rate [47, 48] as shown in Fig. 5 . Tolmetin is also known as 1-methyl-5-p-toluoylpyrrole-2acetic acid or tolectin and belongs to class of non-steroidal anti-inflammatory drug used for osteoarthritis, rheumatoid arthritis, and juvenile arthritis [49, 50] . FDA-approved anticancer drug sunitinib is a tyrosine kinase (RTK) inhibitor used for treating renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST). Because of this, sunitinib is an orally administered formulation that inhibits cellular signaling by targeting multiple RTKs such as rearranged during transfection (RET), colonystimulating factor 1 receptor (CSF-1R), and fms-like tyrosine kinase 3 (flt3) [51, 52] . Organic compounds such as sulfonylureas are used as insulin secretagogues to control type 2 diabetes, thereby reducing blood glucose levels. Glimepiride, a pyrrole analog, secondgeneration sulfonylureas is used for type 2 diabetes mellitus (T2DM) [53, 54] . Literature evidenced an enzyme hydroxymethylglutarylcoenzyme A (HMG-CoA) reductase, known to catalyze the conversion of HMG-CoA to mevalonic acid. This conversion involves compounds that play different roles in lipid metabolism and transport, cholesterol, low-density lipoprotein (LDL), and very-low-density lipoprotein (VLDL) production. Like other statin medications, atorvastatin, a lipid-lowering drug, is also known to inhibit the HMG-CoA reductase, thereby control the endogenous production of cholesterol in the liver, and reduce the risk of cardiovascular disease. Further, combination of atorvastatin and aspirin is used for SARS-CoV-2 infection [55] [56] [57] . Due to significant advances in antiviral drugs, many pyrrolidines ring containing analogs are also reported for their potential inhibitory activity toward different viruses. Like telaprevir, ombitasvir, another antiviral medication, is used as a combination therapy to treat chronic Hepatitis C. This molecule inhibits, more specifically, NS5A, a protein essential for viral replication and virion manifestation. This analog also acts as a potent inhibitor of SARS-CoV-2 [58] [59] [60] . Phensuximide (Fig. 6) , a succinimide analog, possesses antiepileptic and anticonvulsant properties. These orally active drugs produce depolarization-induced accumulation of cyclic adenosine monophosphate and cyclic guanosine monophosphate (cGMP) [61, 62] . Like ombitasvir, pibrentasvir is an anti-hepatitis C virus (HCV) drug and specifically inhibits NS5A that targets the viral RNA replication and virion assembly. Also, in combination with glecaprevir, an NS3/4A protease inhibitor was used for patients with therapeutic failure from other NS5A inhibitors [63, 64] . As such pyrrole and pyrrolidine scaffold itself shows diverse pharmacological properties. However, to attain increased biological activities toward various diseases, many fused pyrrole and pyrrolidine analogs have been reported [65, 66] . Further, these medicinally potent fused analogs have been derived from synthetic routes and isolation [67] [68] [69] [70] . Because of this, present review also focuses very potent fused pyrrole and pyrrolidine analogs. A serotonin receptor antagonist inhibits serotonin (5-HT) receptors that regulate many neurotransmitters such as gamma-aminobutyric acid (GABA), glutamate, dopamine, acetylcholine, and epinephrine or norepinephrine. These receptors modulate many hormones like oxytocin, prolactin, vasopressin, cortisol, and corticotropin. Serotonin receptors were also responsible for aggression, anxiety, memory, learning, nausea, mood, and sleep [71, 72] antagonists, tropisetron, a fused pyrrole, an indole analog blocks the action of serotonin at 5HT3 receptors, resulting in control of nausea and vomiting induced by chemotherapy and radiotherapy [73, 74] . Ketorolac ( Fig. 7) is one more non-steroidal anti-inflammatory drug (NSAID) that belongs to this class. This drug is available as an oral tablet, injection, nasal spray, and eye solution. Due to its analgesic properties, this drug is used, for the treatment of rheumatoid arthritis, postoperative pain, osteoarthritis, menstrual disorders, and as well for spondylitis [75, 76] . FDA-approved kinase inhibitors like ruxolitinib are used for adult patients with bone marrow disorders. Reports suggest that ruxolitinib may use for patients suffering from an infection caused by covid-19. However, this drug is clinically not approved for the treatment of covid-19 disease [77, 78] . Like ruxolitinib, vemurafenib also belongs to the class of competitive kinase inhibitor. Specifically, it is active against serine-threonine kinase (BRAF kinase) with mutant V600E. It binds to the ATP-binding domain of the mutant BRAF and thereby exerts its function. Further, this compound is more effective against severe acute respiratory syndrome corona virus 2 (SARS-CoV-2) [79] [80] [81] . Remdesivir (GS-5734) is chemically named as N- Fig. 8 ). This adenosine triphosphate analog exhibits broad antiviral activity against viral families such as Flaviviridae, Arenaviridae, Coronaviridae, Paramyxoviridae, Pneumoviridae, and Filoviridae. Apart from this, remdesivir is in conditional use for COVID-19 infection as recommended by the World Health Organization [82] [83] [84] [85] [86] . Physostigmine, also known as eserine, a cholinesterase inhibitor, applied topically to the conjunctiva, can cross the blood-brain barrier and acts against anticholinergic toxicity [87] . Carprofen is one more pyrrole analog, non-steroidal antiinflammatory drug (NSAID) used for arthritic symptoms. Previously, carprofen was used for the treatment of gastrointestinal pain and nausea. Later, it is banned due to its toxicity [88, 89] . Literature evidences that Janus kinases belong to the tyrosine protein kinase family. These kinases play a role in the proinflammatory pathway signaling related to autoimmune disorders such as rheumatoid arthritis. Baricitinib, also known as olumiant, is used for rheumatoid arthritis. This analog is a selective and reversible Janus kinase 1 (JAK1) and 2 (JAK2) inhibitors, which disrupt the activation of downstream signaling molecules and proinflammatory mediators [90, 91] . Asenapine is a sublingual tablet used as an antipsychotic to treat patients with bipolar I disorder and schizophrenia [92] . Pemetrexed is a chemotherapy drug sold under the brand name alimta used in combination with cisplatin for patients with malignant pleural mesothelioma and non-squamous non-small cell lung cancer [93, 94] . Ribociclib is a selective anticancer drug and acts as a cyclindependent kinase inhibitor (Fig. 9 ). This drug inhibits specifically cyclin-dependent kinase 4 and 6 (CDK4/6), a protein that enables cancer cells to grow and divide vigorously [95, 96] . Tofacitinib is a small molecule used for rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis [97] . Also, it acts as a Janus kinase (JAK) inhibitor [98] . Ondansetron, one more serotonin 5-HT3 receptor antagonist, is used for cancer patients to avoid nausea and vomiting due to chemotherapy, radiation therapy, or surgery [99] . Further, it prevents inflammation of the gastrointestinal tract [100] . Indomethacin, a benzopyrrole analog, is a nonsteroidal anti-inflammatory drug. The mechanism of action for this drug involves the inhibition of cyclooxygenase, an enzyme responsible for the production of prostaglandins [101] . Pyrrole and pyrrolidine, being an important ring structure, have been found to possess a number of biological activities; this ring has a broad range of biologically active compounds, incorporated either as a substituent or with various substitutions on the ring itself. This review mainly covers recent reports on potential activities of pyrrole and pyrrolidine analogs such as anticancer, antituberculosis, antiviral, and antiinflammatory activity in comparison with earlier reviews that focus on the importance of pyrrole and its analogs until the year 2015-2019 [102] [103] [104] . Epigenetic modification refers to changes that alter the physical structure of DNA. Epigenetic modification involves both DNA methylation and histone modification [105, 106] . These two phenomena play vital role in the regulation of pluripotency genes. Based on the evidence, it has been suggested that most epigenetic therapies for cancer focus modulation of chromatin structure [107, 108] . One such therapy is based on the development of HDAC inhibitors. In view of this, Chen et al. [109] recently reported HDAC/BRD4 dual inhibitors as epigenetic probes. On the basis of structural activity relationship studies, they synthesized three potent pyrrolo-pyridine analogs (30 a-c) as dual inhibitors of HDAC1/BRD4 (Fig. 10) . Based on three-dimensional quantitative structure-activity relationship (3D-QSAR), molecular docking, and molecular dynamics (MD) simulations, Zhang et al. [110] reported target-specific anticancer agents. This investigation suggests that set of thieno[3,2-b]pyrrole (31), as competitive inhibitors of lysine-specific demethylase 1 (LSD1), a histone-modifying enzyme, is overexpressed in various cancers. Further, pyrrole/fused pyrrole analogs have to be explored for target specific anticancer activity [111, 112] . Rasal et al. [113] reported synthesis and antiproliferative activity of series of pyrrole bearing benzimidazole analogs. Among these compounds, only (32) showed significant antiproliferative activity in MDA-MB human cancer cell lines. Many natural products are known to possess potential anticancer activity [114, 115] . One such natural product, pyrrolomycin, a polyhalogenated antibiotic (33 a), has potent anticancer activity. However, this molecule is associated with high cytotoxicity. To overcome this problem, Raimondi et al. [116] designed and synthesized new pyrrolomycins (34 a-c). Their report suggested that newly synthesized compounds with nitro substituent strongly inhibit the proliferation of colon (HCT116) and breast (MCF 7) cancer cell lines in comparison with (33 a). Also, these molecules exhibit good antibacterial activity. Ji et al. [117] reported ruthenium-catalyzed synthesis and antiproliferation activities of poly substituted pyrrolidines. Among these analogs, only compounds (35 a, b) have shown strong antiproliferation activity with IC 50 -2.9 to 16 μM (Fig. 11 ). Investigation reveals that epidermal growth factor receptor (EGFR) and vascular endothelial growth factor receptor (VEGFR) downstream signaling pathways contribute to the tumor growth and progression. So, VEGF and EGFR inhibitors constitute therapies that inhibit different signaling pathways to overcome tumor resistance caused by the inhibition of a single. Because of this, Kuznietsova et al. [118] reported the synthesis of novel pyrrole analogs as protein kinases inhibitors. Their investigation suggested that two compounds, namely chloro-1-(4-chlorobenzyl)-4-((3-(trifluoromethyl)phenyl)amino)-1H-pyrrole-2,5-dione (36 a) and 5-amino-4-(1,3-benzothyazol-2-yn)-1-(3methoxyphenyl)-1,2-dihydro-3H-pyrrole-3-one (36 b), are the competitive inhibitors of EGFR and VEGFR (Fig. 12) . Liu et al. [119] mentioned in their work synthesis and antiproliferative activity of 1-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperazin-1-yl)-2-phenylethan-1-one as Akt This study explains pyrrole analog (39) with trifluoro, phosphonyl, and phenyl group significantly inhibits cell cycle arrest at G1 and induces apoptosis in these cell line with IC 50 (41) has very potential inhibition for the two human pancreatic cancer cell lines such as PANC and ASPC-1. Furthermore, Geretto et al. [125] research on anticancer cancer activity of meso-(p-acetamidophenyl)-calix [4] pyrrole analog suggests that this compound (42) can cross the blood-brain barrier, forms DNA adduct and exhibits significant anticancer activity (Fig. 13 ). Anti-inflammatory agents are the substances that reduce inflammation in the body caused due to the response of vascular tissues to damaged cells, pathogens, or irritants. These compounds prevent this response from the body that causes inflammation. Further, anti-inflammatory agents are used for the prevention and treatment of cancer [126, 127] . Based on this importance, Said Fatahala et al. reported synthesis of pyrrolopyridine and pyrrolopyridopyrimidine analogs as antiinflammatory agents. Their findings reveals that only the fused pyrroles, pyrrolopyridines (43, 44) (Fig. 14) showed good anti-inflammatory activity. Also, molecular docking study shows binding of these analogs with COX-2 [128] . Redzicka et al. [129] research work is based on design, synthesis, molecular docking simulations, and anti-inflammatory activity of series of pyrrolo [3,4-c] pyrrole. According to the results, compounds (45) (46) (47) have shown strong activity toward COX-1 and COX-2. Furthermore, single-crystal X-ray diffraction was recorded for (48). Xue et al. [130] reported the isolation of two nucleosides (49, 50) and two pyrrole analogs (51, 52) (Fig. 15 ) from Cordyceps militaris shown no significant activity against LPS-induced NO production in macrophage-like, Abelson leukemia virus-transformed cell line derived from BALB/c mice (RAW 264.7 cells). Guan reported the isolation of pyrrol-2-aldehyde analogs such as jiangrine G (53), jiangrine A (54), and pyrrolezanthine (55) from the fermentation broth of Jiangella alba and Maytenus austroyunnanensis. Their results based on western blot analysis reveals that all three compounds modulate proinflammatory cytokines via MAPK p38 and NF-κB signaling pathways. Also, compounds (53) and (54) inhibit the expression of iNOS in LPS-induced RAW 264.7 cells [131] . Reale et al. [132] reported synthesis and anti-inflammatory activity of novel series of 1,5-diarylpyrrol-3-sulfur analogs. Further, molecular modeling studies suggest compound (56) (Fig. 16 has potential binding with COX-2 enzyme and showed a significant in vivo anti-inflammatory activity. With the continuation of their work on pyrrolo [3,4-d] pyridazinone, Szczukowski et al. [133] recently reported synthesis and anti-inflammatory activity of novel pyrrolo [3,4-d] pyridazinone analogs bearing 4-aryl-1-(1-oxoethyl)piperazine. Among synthesized compounds, 57 (a, b) and 58 (a, b) inhibit cyclooxygenase, have better affinity to COX-2 isoenzyme, and thereby exert promising anti-inflammatory and anti-oxidant activity (Fig. 17) . Maharjan et al. [134] reported isolation of nine compounds including quinones, fusarubin, ( +)-solaniol, javanicin, 9-desmethylherbarine, and pyrrole analogs; isomers of lucilactaene (59, 60, 61) , (62) , and (63) from roots of Scutellariae baicalensis. These isolated compounds showed potential anti-inflammatory activity by inhibiting NO production and pro-inflammatory cytokines in LPSinduced RAW 264.7 macrophage cells. Mohd Faudzi et al. [135] reported synthesis of twentyfour chalcones of pyrroles as anti-inflammatory agents against nitric oxide (NO) and prostaglandin E 2 (PGE 2 ) controls IFN-γ/LPS-induced RAW 264.7 macrophage cells. Further, these results are supported by the crystal structure and molecular studies (64) (Fig. 18) . More recently, Redzicka et al. [136] reported design, synthesis, and anti-inflammatory activity of N-substituted 3,4-pyrroledicarboximides (65 a-k), (66) and (67 a-d) (Fig. 19) . All the synthesized compounds have shown inhibitory activity against COX-1 and COX-2 cyclooxygenase isoform and thereby exhibit potential activity. Also, this work is supported by QSAR study and X-ray diffraction studies. Antiviral agents are known for their use in viral infections caused by HIV, herpes viruses, hepatitis B and C viruses, influenza A, B viruses, and SARS-CoV-2. A lot of research has been carried out for the development of antivirals and to study their mechanism toward pathogens. However, many antiviral agents have been restricted for their use. The main drawback of the antiviral drug is viruses use the host's cells to replicate. Today, the main difficulty associated with vaccines and antiviral drugs is viral variation and resistance. There will be a real challenge for the medicinal chemist to synthesize safe, specific, and effective antiviral drugs without harming the host [137] [138] [139] [140] . In view of these findings, to find more potent antiviral agents, Tao et al. [141] recently studied effect of GS-441524 (68) (Fig. 20) (71), with optimized antiviral activity against HIV-1, with IC 50 of 89 nM. In addition, the in vitro ADME data suggest improvements in aqueous solubility and other properties of this compound compared to (70) [143] . Hawerkamp et al. [144] reported antiviral activity of tofacitinib, a kind of novel Janus kinase (JAK) inhibitor in keratinocytes. This study reveals that tofacitinib reduces T cell activation and down regulates gene regulation. Based on the importance of porphyrin and its metal complexes, Sengupta et al. [145] synthesized novel Zn (II) complexes of nitro porphyrin derivatives (72, 73) (Fig. 21) and carried out anticancer and antivira l activities. This metal complexes showed very good anticancer activity against human lung cancer cell-line A549 and improved antiviral activity against a HIV-1 and SIVmac. In the year 2020, Liu et al. [146] reported the synthesis of dihydopyrrolidines. These analogs were screened for antiinfluenza activity. Among these analogs, (74 a-d) (Fig. 22 ) has shown potetinal activity against IAVs with IC 50 ranges Pyrrole, purine analogs as potential antiviral agents-II from 3.11 to 9.23 μM. This investigation further illustrates that these compounds suppress NDAPH oxidase, NOX1 in MDCK cells. Like human alphaherpesvirus 2 (HHV-2), Caprine alpha herpesvirus 1 (CpHV-1) causes the genital disorder. Because of this, Lanave et al. [147] studied the antiviral efficacy of compound PHA767491, fused pyrrole (75) toward HSV-1 and HSV-2 in vitro and as well in the mouse model. Yao et al. [148] reported isolation and anti-hepatitis B virus activity of natural products delicatulines A (76) and B (77), an adenine analogs and pyrrole analog (78) . Their study is based on n-BuOH extract of Selaginella delicatula. Further, none of these compounds and few known compounds have exhibited better anti-HBV activity. Based on colorimetric viral infection and qRT-PCR assays, Liu et al. [149] studied sodium copper chlorophyllin (79) as potential antiviral agent against infection caused by divergent EV-A71 and coxsackievirus-A16 (CV-A16). In addition, viral gastroenteritis has become serious concern for children caused by rotavirus, coxsackievirus, and adenovirus which are the most common viruses that cause gastroenteritis. Taking this into consideration, Mohamed et al. reported synthesis and antiviral activity of pyrrolo [2,3-d] pyrimidine and pyrrolo [3,2-e] [1, 2, 4] triazolo [4,3-c] pyrimidine analogs against gastroenteric viral infections. Screening of the new compounds for anti-viral activities against Rotavirus Wa strain and coxsackievirus B4 suggests that compounds (80 a-e), (81 a-c) and (82 a-c) (Fig. 23 ) exhibited significant antiviral activity [150] . Another virus, the novel SARS-CoV-2 that causes coronavirus disease 2019 (COVID-19) results in an inevitable pandemic. Development of antiviral drug against SARS-CoV-2 is considered to be real challenge. Fakhar et al. [154] report based on the structure-based pharmacophore modeling, virtual screening workflow, ADMET, and molecular dynamics simulations revealed that compound ABBV-744 (87) has a strong affinity (ΔGbind − 45.43 kcal/mol) to the main protease. Further, this study also considered the other two compounds (88, 89) as potential inhibitors of SARS-CoV-2. In the year 2021, by the experimental evidence, Varghese et al. [155] have proposed a combination of obatoclax and berberine as possible antiviral drugs for SARS-CoV-2 infection (Fig. 24 ). Today, treatment for multidrug-resistant (MDR) tuberculosis (TB) has become a real challenge [156] . Tuberculosis is an infection caused by gram-positive bacteria mycobacterium tuberculosis. This disease is treated with first-line drugs like isoniazid, rifampin, pyrazinamide, ethambutol, and streptomycin [157] . Second Liu et al. [163] used virtual high-throughput screening, in vitro assay, and synthesized 1-(2-chloro-6-fluorobenzyl)-2,5-dimethyl-4-((phenethylamino)methyl)-1H-pyrrole-3-carboxylate (92) as anti-tubercular agents that inhibit ClpP1P2 peptidase in M. tuberculosis. Many nitrogen-containing heterocyclic compounds were designed, synthesized, and screened for their biological activities [164, 165] . However, pyrrole and pyrrolidine analogs have been attracted more for their diverse pharmacological activities [166] . By finding these significances in the literature, Joshi et al. [167] reported the synthesis and antimycobacterial activity of novel pyrrolyl benzamide derivatives against M. tuberculosis H37Rv and enoyl-ACP reductase enzyme. Compounds (93a-e) have shown significant InhA inhibitory activity. Furthermore, Poce et al. [168] reported pyrrole analog (94) as potential inhibitor of mycobacteria. Their study is based on synthesis of pyrrole analog by the variations in hit compound (95) . More recently, Arumugam et al. [169] synthesized new spirooxindolopyrrolidine-embedded indandione for in vitro anti-tubercular activity against Mycobacterium tuberculosis H37Rv. Their results suggest that chlorinesubstituted indandione (96 a, b) displayed potential activity with MIC 0.78 μg/mL compared to ethambutol having MIC of 1.56 μg/mL as shown in Fig. 26 . Eng et al. [170] reported as synthesis of [3R,4R]-4-Hypoxanthin-9-yl-3-((S)-2-hydroxy-2-phosphonoethyl) oxy-1-N-(phosphonopropionyl)pyrrolidine and [3R,4R]-4-guanin-9-yl-3-((S)-2-hydroxy-2-phosphonoethyl)oxy-1-N-(phosphonopropionyl)pyrrolidine as potent inhibitors of hypoxanthine-guanine phosphoribosyltransferase (HGPRT) with K i values of 60 nM. Krause et al. [171] reported synthesis and antimycobacterial activity of series of new 4-substituted picolinohydrazonamides. Among these compounds, (98) acts as antimycobacterial agent with MIC 0.4 μg/mL. Based on the literature survey, it has been suggested that compared to pyrrole analogs, pyrrolidine scaffold will be having more preference to the drug design because of unrestricted conformation of the ring [172] . Further, pyrrolidine analog has privileged N − 1 position for substitutions which were present in US FDA-approved drugs [173] . We restricted this review on pyrrole, pyrrolidine, and its therapeutic potential for the aspects such as anticancer, anti-inflammatory, antiviral, and antimycobacterial activity. Other biological activities of this scaffold deserve special attention. The literature evidenced five-membered nitrogen-containing pyrrole and pyrrolidine have been known for their extensive biological and pharmacological activities. Many biomolecules have possessed either pyrrole, pyrrolidine, or fused pyrrole. Using structure-activity relationship and molecular docking studies, pyrrole and pyrrolidine analogs have been designed, synthesized, and screened for diverse therapeutic activities. Based on the comprehensive literature on the importance of these molecules, this review mainly highlights recent reports on these versatile molecules for anti-cancer, anti-inflammatory, antiviral, and antitubercular activity. Also, this review focuses on the pyrrole, pyrrolidine, and fused pyrrole-containing drug candidates. This review will be a useful platform for innovative researchers to work on pyrrole analogs to overcome drug resistance and toxicity. Recent studies of nitrogen containing heterocyclic compounds as novel antiviral agents: a review A review: biologically active 3,4-heterocycle-fused coumarins Heterocycles in the treatment of neglected tropical diseases A comprehensive review on pyrimidine analogs-versatile scaffold with medicinal and biological potential A comprehensive review on the biological interest of quinoline and its derivatives The requirement for cobalt in vitamin B 12 : a paradigm for protein metalation A transcriptomic approach to the metabolism of tetrapyrrolic photosensitizers in a marine annelid Heme degradation in pathophysiology of and counter measures to inflammation-associated disease Pyrrolic and dipyrrolic chlorophyll degradation products in plants and herbivores Meso-and β-pyrrole-linked chlorin-bacteriochlorin dyads for promoting far-red fret and singlet oxygen production Pathogenesis and clinical features of the acute hepatic porphyrias (AHPs) Another look at pyrroloiminoquinone alkaloids-perspectives on their therapeutic potential from known structures and semisynthetic analogues Pathological conformations of disease mutant ryanodine receptors revealed by cryo-EM A Total synthesis of rhazinilam through gold-catalyzed cycloisomerization-sulfonyl migration and palladium-catalyzed suzuki-miyaura coupling of pyrrolyl sulfonates The rhazinilam-leuconoxinemersicarpine triad of monoterpenoid indole alkaloids Lamellarin 14, a derivative of marine alkaloids, inhibits the T790M/C797S mutant epidermal growth factor receptor Prodigiosin inhibits bacterial growth and virulence factors as a potential physiological response to interspecies competition Synthetic and theoretical investigations of myrmicarin biosynthesis Sceptrin, a marine natural compound, inhibits cell motility in a variety of cancer cell lines In vitro screening and in silico prediction of antifungal metabolites from rhizobacterium Achromobacter kerstersii JKP9 A new potent antimicrobial metalloporphyrin Anti-inflammatory effects of atorvastatin treatment in chronic obstructive pulmonary disease. A controlled pilot study Torcetrapib/atorvastatin combination therapy Synthesis and biological evaluation of anti-tubercular activity of schiff bases of 2-Amino thiazoles Identification of 2-substituted pyrrolo[1,2-b]pyridazine derivatives as new PARP-1 inhibitors Penetrating the blood-brain barrier with new peptide-porphyrin conjugates having anti-hiv activity Targeting the mutant PIK3CA gene by DNA-alkylating pyrroleimidazole polyamide in cervical cancer Structural and biological investigations for a series of n-5 substituted pyrrolo [3,2-d] pyrimidines as potential anticancer therapeutics Efficacy of vonoprazan for helicobacter pylori eradication Tofacitinib: a review in psoriatic arthritis Pyrrole: an insight into recent pharmacological advances with structure activity relationship The potential of sunitinib as a therapy in ovarian cancer Recent advances in nanoparticle carriers for coordination complexes Bioinspired polydopamine-coated hemoglobin as potential oxygen carrier with antioxidant properties Myoglobin structure and function: a multiweek biochemistry laboratory project Role of vitamin B12 deficiency in ischemic stroke risk and outcome Bilirubin as a metabolic hormone: the physiological relevance of low levels Agelasine Diterpenoids and Cbl-b inhibitory ageliferins from the coralline demosponge astrosclera willeyana The nargenicin family of oxabridged macrolide antibiotics Bioactivities of a new pyrrolidine alkaloid from the root barks of Orixa japonica Pyrrolidine alkaloids and their promises in pharmacotherapy Nitrogencontaining heterocycles as anticancer agents: an overview. Anticancer Levetiracetam: a comprehensive review Small molecule degraders of the hepatitis C virus protease reduce susceptibility to resistance mutations Uncovering flexible active site conformations of sars-cov-2 3cl proteases through protease pharmacophore clusters and COVID-19 Drug Repurposing Ombitasvir/paritaprevir/ritonavir + dasabuvir +/-ribavirin in real world hepatitis C patients Evaluation of dual inhibitory effect of anagliptin, ramipril, and lisinopril on angiotensin-converting enzyme and dpp-4 activities Angiotensin-converting enzyme inhibitor reduces radiation-induced periprosthetic capsular fibrosis Pharmaceutical and pharmacokinetic evaluation of novel rectal mucoadhesive hydrogels containing tolmetin sodium Tolmetin sodium-loaded thermosensitive mucoadhesive liquid suppositories for rectal delivery; strategy to overcome oral delivery drawbacks Efficacy and safety of nivolumab plus ipilimumab versus sunitinib in first-line treatment of patients with advanced sarcomatoid renal cell carcinoma Therapeutic drug monitoring of oral targeted antineoplastic drugs Pharmacogenetic-guided glimepiride therapy in type-2 diabetes mellitus: a cost-effectiveness study Continuous spectrum of glucose dysmetabolism due to the KCNJ11 gene mutation-Case reports and review of the literature Atorvastatin in combination with radiotherapy and temozolomide for glioblastoma: a prospective phase II study Pharmaceutical evaluation of atorvastatin-loaded nanostructured lipid carriers incorporated into the gelatin/hyaluronic acid/polycaprolactone scaffold for the skin tissue engineering Atorvastatin and aspirin as adjuvant therapy in patients with sarscov-2 infection: a structured summary of a study protocol for a randomised controlled trial Efficacy and safety of ombitasvir plus paritaprevir, ritonavir and ribavirin in non-cirrhotic treatment-naïve and treatment-experienced egyptians with chronic HCV genotype-4 infection Baroiu Liliana et al (2021) Effectiveness of 8-and 12-Week treatment with ombitasvir/ paritaprevir/ritonavir and dasabuvir in treatment-naïve HCV patients in a real-life setting in Romania: the AMETHYST study Identification of 3-chymotrypsin like protease (3CLPro) inhibitors as potential anti-SARS-CoV-2 agents HPO-Shuffle: an associated gene prioritization strategy and its application in drug repurposing for the treatment of canine epilepsy Plasma concentrations of phensuximide, methsuximide, and their metabolites in relation to clinical efficacy Effect of baseline resistance-associated substitutions on the efficiency of glecaprevir/ pibrentasvir in chronic hepatitis C subjects: a meta-analysis Real-world outcomes in historically underserved patients with chronic hepatitis c infection treated with glecaprevir/pibrentasvir An overview of the biological activity of pyrrolo[3,4-c]pyridine derivatives Lamellarin alkaloids: isolation, synthesis, and biological activity Modular and stereoselective approach to highly substituted indole/pyrrole-fused diazepanones Copper-catalyzed asymmetric reaction of alkenyl diynes with styrenes by formal [3 + 2] cycloaddition via cu-containing all-carbon 1,3-dipoles: access to chiral pyrrole-fused bridged [2.2.1] skeletons An insight into the advanced synthetic recipes to access ubiquitous indole heterocycles Synthesis and biological screening of new cyano-substituted pyrrole fused (iso)quinoline derivatives Impact of specific serotonin receptor modulation on behavioral flexibility Pharmacological evidence for transactivation within melatonin MT2 and serotonin 5-HT2C receptor heteromers in mouse brain Conformational transitions of the serotonin 5-HT3 receptor Synthesis and development of indole based 5-ht3 receptor antagonists as anti-emetic drugs in oncology: an update A usage analysis of ketorolac in the emergency department The nonsteroidal anti-inflammatory drug ketorolac alters the small intestinal microbiota and bile acids without inducing intestinal damage or delaying peristalsis in the rat Primary myelofibrosis: update on diagnosis, risk-stratification and management Compassionate use of JAK1/2 inhibitor ruxolitinib for severe COVID-19: a prospective observational study Systematic review of BRAF/MEK inhibitors-induced severe cutaneous adverse reactions (SCARs) Comment on: Response to the BRAF/MEK inhibitors dabrafenib/trametinib in an adolescent with a BRAF V600E mutated anaplastic ganglioglioma intolerant to vemurafenib Identification and tracking of antiviral drug combinations Remdesivir: first approval Removal of remdesivir's metabolite gs-441524 by hemodialysis in a double lung transplant recipient with COVID-19 Vaporization, bioactive formulations and a marine natural product: different perspectives on antivirals Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial New perspectives on antimicrobial agents: remdesivir treatment for COVID-19 A randomized trial comparing physostigmine vs lorazepam for treatment of antimuscarinic (anticholinergic) toxidrome The non-steroidal anti-inflammatory drug carprofen negatively impacts new bone formation and antibiotic efficacy in a rat model of orthopaedic-device-related infection Anti-Inflammatory effect of carprofen is enhanced by avocado/soybean unsaponifiables, glucosamine and chondroitin sulfate combination in chondrocyte microcarrier spinner culture State of the art: approved and emerging JAK inhibitors for rheumatoid arthritis Baricitinib treatment resolves lower-airway macrophage inflammation and neutrophil recruitment in SARS-CoV-2-infected rhesus macaques A review of asenapine in the treatment of bipolar disorder AURA3 Investigators. osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer Randomized phase III study of pemetrexed plus cisplatin versus vinorelbine plus cisplatin for completely resected stage II to IIIA nonsquamous non-small-cell lung cancer Cyclin-dependent kinase 4/6 inhibitors and interstitial lung disease in the FDA adverse event reporting system: a pharmacovigilance assessment Inhibiting CDK4/6 in breast cancer with palbociclib, ribociclib, and abemaciclib: similarities and differences Update on the safety profile of tofacitinib in rheumatoid arthritis from clinical trials to real-world studies: a narrative review Pharmacology and safety of tofacitinib in ulcerative colitis Comparison of ondansetron and tropisetron in preventing postoperative nausea and vomiting: a meta-analysis of randomized controlled trials Multi-dose oral ondansetron for pediatric gastroenteritis: study protocol for the multi-dose oral ondansetron for pediatric acute gastroenteritis (DOSE-AGE) pragmatic randomized controlled trial Clinical pharmacology of indomethacin in preterm infants: implications in patent ductus arteriosus closure Pyrrole: an emerging scaffold for construction of valuable therapeutic agents Tofacitinib: a Review in rheumatoid arthritis Bioactive pyrrole-based compounds with target selectivity Active turnover of DNA methylation during cell fate decisions Epigenetic mechanisms regulating COVID-19 infection HnRNPA2 is a novel histone acetyltransferase that mediates mitochondrial stress-induced nuclear gene expression Probing p300/CBP associated factor (PCAF)-dependent pathways with a small molecule inhibitor Discovery of selective HDAC/BRD4 dual inhibitors as epigenetic probes Molecular docking, 3D-QSAR, and molecular dynamics simulations of thieno[3,2-b]pyrrole derivatives against anticancer targets of KDM1A/LSD1 Epigenetic modifications in prostate cancer Epigenetic alterations in the gastrointestinal tract: current and emerging use for biomarkers of cancer Potential 2,4-dimethyl-1H-pyrrole-3-carboxamide bearing benzimidazole template: design, synthesis, in vitro anticancer and in silico ADME study A comprehensive insight on the biological potential of embelin and its derivatives Inhibition of STAT3 dimerization and acetylation by garcinol suppresses the growth of human hepatocellular carcinoma in vitro and in vivo New synthetic nitro-pyrrolomycins as promising antibacterial and anticancer agents Synthesis and biological evaluation of substituted pyrrolidines and pyrroles as potential anticancer agents Pyrrole derivatives as potential anti-cancer therapeutics: synthesis, mechanisms of action, safety Extensive investigation of benzylic N-containing substituents on the pyrrolopyrimidine skeleton as Akt inhibitors with potent anticancer activity A domino annulation approach to 3,4-diacylpyrrolo[1,2-a]pyrazines: decoration of pyrazine units A novel trifluoromethyl 2-phosphonopyrrole analogue inhibits human cancer cell migration and growth by cell cycle arrest at G1 phase and apoptosis Folate-gold-bilirubin nanoconjugate induces apoptotic death in multidrug-resistant oral carcinoma cells -(methylsulfonyl)piperazin-1-yl)methyl)-4-morpholinopyrrolo[2,1-f][1,2,4]triazin-2-yl)-4-(trifluoromethyl)pyridin-2-yl)carbamate (CYH33) as an orally bioavailable, highly potent, PI3K alpha inhibitor for the treatment of advanced solid tumors Onepot synthesis of substituted pyrrole-imidazole derivatives with anticancer activity A novel calix[4]pyrrole derivative as a potential anticancer agent that forms genotoxic adducts with Anti-inflammatory agents: present and future Anti-Inflammatory drugs as anticancer agents Pyrrole and fused pyrrole compounds with bioactivity against inflammatory mediators COX-1/COX-2 inhibition activities and molecular docking study of newly designed and synthesized pyrrolo[3,4-c]pyrrole Mannich bases A new nucleoside and two new pyrrole alkaloid derivatives from Cordyceps militaris The antiinflammatory effects of jiangrines from Jiangella alba through inhibition of p38 and NF-κB signaling pathways Synthesis, biological evaluation and molecular modeling of novel selective COX-2 inhibitors: sulfide, sulfoxide, and sulfone derivatives of 1,5-diarylpyrrol-3-substituted scaffold Design, Synthesis and comprehensive investigations of pyrrolo[3,4-d]pyridazinone-based 1,3,4-oxadiazole as new class of selective cox-2 inhibitors Isolation of unstable isomers of lucilactaene and evaluation of anti-inflammatory activity of secondary metabolites produced by the endophytic fungus Fusarium sp. Q F001 from the roots of Scutellaria baicalensis Inhibition of nitric oxide and prostaglandin E2 production by pyrrolylated-chalcones: synthesis, biological activity, crystal structure analysis, and molecular docking studies Design and synthesis of n-substituted 3,4-pyrroledicarboximides as potential anti-inflammatory agents Antiviral therapeutics Antiviral agents: discovery to resistance Recent progress of antiviral therapy for coronavirus disease 2019 Remdesivir: from Ebola to COVID-19 Comparison of anti-SARS-CoV-2 activity and intracellular metabolism of remdesivir and its parent nucleoside Anti-norovirus activity of C7-modified 4-amino-pyrrolo[2,1-f] [1,2,4]triazine C-nucleosides Preclinical optimization of gp120 entry antagonists as anti-hiv-1 agents with improved cytotoxicity and ADME properties through rational design, synthesis, and antiviral evaluation Tofacitinib downregulates antiviral immune defence in keratinocytes and reduces T cell activation Dual activity of amphiphilic Zn(II) nitroporphyrin derivatives as HIV-1 entry inhibitors and in cancer photodynamic therapy Discovery of dihydropyrrolidones as novel inhibitors against influenza a virus Antiviral activity of PHA767491 on Caprine alpha herpesvirus 1 in vitro New adenine analogues and a pyrrole alkaloid from Selaginella delicatula Sodium copper chlorophyllin is highly effective against enterovirus (ev) a71 infection by blocking its entry into the host cell Evaluation of novel pyrrolopyrimidine derivatives as antiviral against gastroenteric viral infections Potential antiviral options against SARS-CoV-2 infection Reckoning a fungal metabolite, pyranonigrin a as a potential main protease (M pro ) inhibitor of novel SARS-CoV-2 virus identified using docking and molecular dynamics simulation Broad-spectrum antivirals of protoporphyrins inhibit the entry of highly pathogenic emerging viruses ABBV-744 as a potential inhibitor of SARS-CoV-2 main protease enzyme against COVID-19 Berberine and obatoclax inhibit SARS-Cov-2 replication in primary human nasal epithelial cells in vitro Treatment of multidrug-resistant and extensively drug-resistant tuberculosis in children: the role of bedaquiline and delamanid The impact of first-line anti-tubercular drugs' pharmacokinetics on treatment outcome: a systematic review Resistant tuberculosis: the latest advancements of second-line antibiotic inhalation products Multidrug-resistant tuberculosis in children and adolescents: current strategies for prevention and treatment Structure of mycobacterial ATP synthase bound to the tuberculosis drug bedaquiline Novel isoniazid derivative as promising antituberculosis agent Synthesis and biological evaluation of 1H-pyrrolo[2,3-d]pyrimidine-1,2,3-triazole derivatives as novel anti-tubercular agents Design, synthesis and biological evaluation of novel pyrrole derivatives as potential ClpP1P2 inhibitor against Mycobacterium tuberculosis Synthesis and antimicrobial evaluation of 5-iodopyrimidine analogs Cyclization of 4-(2-minoanilino)-2-benzylthiopyrimidine to novel 1-(2-benzylthiopyrimidin-4-yi Current trends in pyrrole and porphyrinderived nanoscale materials for biomedical applications Pharmacophore mapping, molecular docking, chemical synthesis of some novel pyrrolyl benzamide derivatives and evaluation of their inhibitory activity against enoyl-ACP reductase (InhA) and Mycobacterium tuberculosis In vivo potent BM635 analogue with improved drug-like properties Stereoselective synthesis and discovery of novel spirooxindolopyrrolidine engrafted indandione heterocyclic hybrids as antimycobacterial agents Pyrrolidine nucleoside bisphosphonates as antituberculosis agents targeting hypoxanthine-guanine phosphoribosyltransferase 2020) 4-Substituted picolinohydrazonamides as a new class of potential antitubercular agents Pyrrolidine in drug discovery: a versatile scaffold for novel biologically active compounds Analysis of the structural diversity, substitution patterns, and frequency of nitrogen heterocycles among US FDA approved pharmaceuticals Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations Acknowledgements Authors are thankful to Dr. N.M. Goudgaon, professor (RTD), Department of Chemistry, Gulbarga University, Gulbarga, Karnataka, India, for his constant encouragement. Authors are also thankful to management of the college for providing necessary facility for the completion of this review article.Author contributions Jeelan basha N involved in conceptualization, methodology, software, data curation, writing-original draft preparation, writing-reviewing and editing, supervision. Basavarajaiah SM took part in writing-reviewing and editing, methodology, and software. Shyamsunder K involved in methodology and software.